{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:40:50Z","timestamp":1777869650781,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.trim.2019.101226","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T19:38:00Z","timestamp":1563824280000},"page":"101226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study"],"prefix":"10.1016","volume":"56","author":[{"given":"Katie","family":"Korneffel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Mitro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"Buschor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.trim.2019.101226_bb0005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-2277.2012.01448.x","article-title":"Alemtuzumab as compared to alternative contemporary induction regimens","volume":"25","author":"LaMattina","year":"2012","journal-title":"Transpl. Int."},{"issue":"9","key":"10.1016\/j.trim.2019.101226_bb0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1432-2277.2006.00343.x","article-title":"The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation","volume":"19","author":"Magliocca","year":"2006","journal-title":"Transpl. Int."},{"issue":"11","key":"10.1016\/j.trim.2019.101226_bb0015","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1432-2277.2011.01315.x","article-title":"Single shot of alemtuzumab as induction therapy after kidney transplantation is sufficient","volume":"24","author":"Boesmueller","year":"2011","journal-title":"Transpl. Int."},{"issue":"20","key":"10.1016\/j.trim.2019.101226_bb0020","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.trim.2019.101226_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.nefro.2016.03.019","article-title":"Lymphocyte-depleting induction and steroid minimization after kidney transplantation: a review","volume":"36","author":"Naesens","year":"2016","journal-title":"Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia."},{"issue":"10","key":"10.1016\/j.trim.2019.101226_bb0030","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2019.101226_bb0035","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/TP.0b013e3181dc0999","article-title":"Evaluation of low-dose rituximab induction therapy in living related kidney transplantation","volume":"89","author":"Takagi","year":"2010","journal-title":"Transplantation."},{"issue":"1","key":"10.1016\/j.trim.2019.101226_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.transproceed.2011.12.063","article-title":"Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study","volume":"44","author":"Kim","year":"2012","journal-title":"Transplant. Proc."},{"issue":"Suppl. 3","key":"10.1016\/j.trim.2019.101226_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2019.101226_bb0050","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/tri.12629","article-title":"Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?","volume":"28","author":"Fehr","year":"2015","journal-title":"Transpl. Int."},{"issue":"3","key":"10.1016\/j.trim.2019.101226_bb0055","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.transproceed.2009.01.067","article-title":"Prevention of cytomegalovirus disease in renal transplantation: single-center experience","volume":"41","author":"Parreira","year":"2009","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2019.101226_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12780","article-title":"Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: single-center experience","volume":"19","author":"Khan","year":"2017","journal-title":"Transplant Infectious Disease: An Official Journal of the Transplantation Society."},{"issue":"6","key":"10.1016\/j.trim.2019.101226_bb0065","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/tid.12609","article-title":"Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+\/R+) renal transplant recipients","volume":"18","author":"Heldenbrand","year":"2016","journal-title":"Transplant Infectious Disease: An Official Journal of the Transplantation Society."},{"issue":"6","key":"10.1016\/j.trim.2019.101226_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.transproceed.2016.05.004","article-title":"Extended low-dose valganciclovir is effective prophylaxis against cytomegalovirus in high-risk kidney transplant recipients with near-complete eradication of late-onset disease","volume":"48","author":"Fayek","year":"2016","journal-title":"Transplant Proc."},{"issue":"4","key":"10.1016\/j.trim.2019.101226_bb0075","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood-2007-03-080010","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O'Brien","year":"2008","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.trim.2019.101226_bb0080","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America."},{"issue":"11","key":"10.1016\/j.trim.2019.101226_bb0085","doi-asserted-by":"crossref","first-page":"F925","DOI":"10.1152\/ajprenal.00317.2015","article-title":"Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies","volume":"309","author":"Erdbrugger","year":"2015","journal-title":"American Journal of Physiology Renal Physiology."},{"issue":"2","key":"10.1016\/j.trim.2019.101226_bb0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2004.00692.x","article-title":"Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report","volume":"5","author":"Preiksaitis","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2019.101226_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1100\/2012\/820621","article-title":"Viral infection in renal transplant recipients","volume":"2012","author":"Cukuranovic","year":"2012","journal-title":"Sci. World J."},{"issue":"4","key":"10.1016\/j.trim.2019.101226_bb0100","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/tid.12247","article-title":"Current characteristics and outcome of cytomegalovirus infections after kidney transplantation","volume":"16","author":"Helantera","year":"2014","journal-title":"Transplant Infectious Disease: An Official Journal of the Transplantation Society."},{"issue":"6","key":"10.1016\/j.trim.2019.101226_bb0105","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.transproceed.2009.06.005","article-title":"Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+\/R-) liver transplant recipients: a single-center experience","volume":"41","author":"Montejo","year":"2009","journal-title":"Transplant. Proc."},{"issue":"5","key":"10.1016\/j.trim.2019.101226_bb0110","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2019.101226_bb0115","first-page":"897","article-title":"Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation","volume":"23","author":"Leone","year":"2010","journal-title":"Transpl. Int."},{"issue":"3","key":"10.1016\/j.trim.2019.101226_bb0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/ciq143","article-title":"Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis","volume":"52","author":"Kalil","year":"2011","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America."},{"issue":"8","key":"10.1016\/j.trim.2019.101226_bb0125","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/ajt.12298","article-title":"CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction","volume":"13","author":"Gatault","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.trim.2019.101226_bb0130","doi-asserted-by":"crossref","first-page":"Cr609","DOI":"10.12659\/MSM.882045","article-title":"Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients","volume":"17","author":"van Ree","year":"2011","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research."},{"issue":"3","key":"10.1016\/j.trim.2019.101226_bb0135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.transproceed.2011.11.053","article-title":"Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors","volume":"44","author":"Cordero","year":"2012","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.trim.2019.101226_bb0140","first-page":"253","article-title":"Cytomegalovirus infection in kidney transplant patients: what is the best way to prevent it?","volume":"28","author":"Martin-Davila","year":"2008","journal-title":"Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia."},{"issue":"1","key":"10.1016\/j.trim.2019.101226_bb0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-6143.2012.04314.x","article-title":"BK virus replication and nephropathy after Alemtuzumab-induced kidney transplantation","volume":"13","author":"Theodoropoulos","year":"2013","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2019.101226_bb0150","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/TP.0b013e3182a6890d","article-title":"CMV viremia is associated with a decreased incidence of BKV reactivation after kidney and kidney-pancreas transplantation","volume":"96","author":"Elfadawy","year":"2013","journal-title":"Transplantation."},{"issue":"7","key":"10.1016\/j.trim.2019.101226_bb0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients","volume":"347","author":"Hirsch","year":"2002","journal-title":"N. Engl. J. Med."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632741930067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632741930067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:59:02Z","timestamp":1760810342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096632741930067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":31,"alternative-id":["S096632741930067X"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2019.101226","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2019.101226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101226"}}